Navigation Links
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
Date:10/9/2007

Results Expected to be Delivered by November 2007

BARCELONA, Spain, October 9 /PRNewswire/ -- This double-blind, placebo-controlled and multi-center Phase II trial includes 332 patients with Overactive Bladder (OAB) and has been conducted at 77 sites in 11 countries (US, Germany, Spain, The Netherlands, Czech Republic, Hungary, Poland, Russia, South Africa, New Zealand and Australia). The company expects to report the results of this trial during November.

The total study treatment duration after screening and baseline has been 4 weeks. Patients have been randomized into one of five treatment arms, which include one placebo, one active control (Tolterodine, 4 mg once daily) and three SVT-40776 groups (once daily administration). The primary endpoint of the trial is the mean change from baseline to last day of treatment in the number of micturitions per day. The trial will also generate tolerability data.

"The successful completion of patient enrollment in this clinical trial represents an important milestone in the development of SVT-40776" said Jordi Julve, CEO.

"We are very excited to look at the data regarding the efficacy and safety of SVT-40776 and to confirm the excellent profile suggested by our previous clinical data. We expect that SVT-40776 will improve the efficacy/tolerability ratio compared to the current available treatments, being the treatment of choice for patients with OAB" continued Mr. Julve.

About SVT-40776

SVT-40776 is a new potent and selective M3 muscarinic antagonist for the treatment of OAB with high bladder/salivary gland selectivity, long half life and low metabolic rate. Compared to oxybutynin, tolterodine, solifenacin and darifenacin, SVT-40776 is the most potent and selective M3 vs M2 yet developed. This profile is expected to give SVT-40776 an improved efficacy and tolerability, increasing the benefit/risk ratio.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. In 2006 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments, e.g. CETRAXAL eardrops (currently under US-FDA review) and by emphasizing collaborations regarding its pipeline products.

Contact:

Cristina Viayna,

Business Development & Licensing

cviayna@salvatbiotech.com

http://www.salvatbiotech.com


'/>"/>
SOURCE SALVAT
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
3. Milwaukee takes another step in electronic patient data exchange
4. What patients want: A story of choice, clinical trials & evidence-based medicine
5. GE partner allows real-time access to patient data
6. Sun, TeraMedica solution aimed at doctor-patient relationship
7. Interview: Dr. William Yasnoff on patient-centric IT
8. Video game technology could improve physician-patient interactions
9. GE and Intermountain want to streamline nationwide patient data
10. Human factors and IT: Designing for patient safety
11. The challenges of maintaining patient privacy and delivering secure clinical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy ... history, it is offering its 2016 AAT Member Certification Qualification Course for Technicians via ... for the webinar, which will include a detailed review of hardware, software, and camera ...
(Date:2/9/2016)... Lawrenceville, NJ (PRWEB) , ... February 09, 2016 ... ... Diane Dorman, former Vice President for Public Policy for the National Organization for ... and patient advocacy groups to ensure their voices are heard throughout the drug ...
(Date:2/9/2016)... Feb. 9, 2016 This market research report ... and future prospects of the market in terms of ... companies engaged in the manufacture of microbiology culture media ... with a market snapshot providing the overall information of ... report. This section also provides the overall information and ...
(Date:2/9/2016)... -- Three-Year Initiative Supports Next Generation of Medical ... Life-Changing Camp Experiences ... the lives of children born with rare diseases, as well as ... is announcing a new initiative designed to positively affect the lives ... of rare disease care. --> To mark the company,s ...
Breaking Biology Technology:
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
(Date:1/20/2016)... -- A market that just keeps on growing. Molecular ... in genomics knowledge. Learn all about it in this ... dynamic trends are pushing market growth and company valuations. ... - pathogen evolution - next generation sequencing - emergence ... of the role of genetic material in Disease and ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):